NAMS Stock Overview
A late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
NewAmsterdam Pharma Company N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.01 |
| 52 Week High | US$26.35 |
| 52 Week Low | US$8.90 |
| Beta | -0.00091 |
| 11 Month Change | 5.21% |
| 3 Month Change | 21.05% |
| 1 Year Change | 102.33% |
| 33 Year Change | 104.39% |
| 5 Year Change | n/a |
| Change since IPO | 85.28% |
Recent News & Updates
Obicetrapib Positions NewAmsterdam Pharma For Significant Market Growth In Cardiovascular Therapies
Oct 04Will NewAmsterdam Pharma (NASDAQ:NAMS) Spend Its Cash Wisely?
Oct 01
Recent updates
Shareholder Returns
| NAMS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -18.7% | -6.5% | -1.0% |
| 1Y | 102.3% | 14.6% | 30.3% |
Return vs Industry: NAMS exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: NAMS exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| NAMS volatility | |
|---|---|
| NAMS Average Weekly Movement | 8.1% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NAMS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NAMS's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 62 | Michael Davidson | www.newamsterdampharma.com |
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease.
NewAmsterdam Pharma Company N.V. Fundamentals Summary
| NAMS fundamental statistics | |
|---|---|
| Market cap | US$2.19b |
| Earnings (TTM) | -US$198.92m |
| Revenue (TTM) | US$33.59m |
55.0x
P/S Ratio-9.3x
P/E RatioIs NAMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NAMS income statement (TTM) | |
|---|---|
| Revenue | US$33.59m |
| Cost of Revenue | US$0 |
| Gross Profit | US$33.59m |
| Other Expenses | US$232.51m |
| Earnings | -US$198.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.15 |
| Gross Margin | 100.00% |
| Net Profit Margin | -592.12% |
| Debt/Equity Ratio | 0% |
How did NAMS perform over the long term?
See historical performance and comparison